东阿阿胶生物药前景看好
重组(zu)人(ren)白介素－１１（Ⅰ）获得(de)国家一类新药证书(shu)
东阿(a)(a)阿(a)(a)胶研(yan)发(fa)的具(ju)有(you)自主知识产权的基因工(gong)程国家(jia)(jia)一类新(xin)(xin)(xin)药(yao)(yao)重(zhong)(zhong)组人(ren)(ren)白(bai)介(jie)素－１１（Ⅰ）日前获国家(jia)(jia)新(xin)(xin)(xin)药(yao)(yao)证书和药(yao)(yao)品注册批件。重(zhong)(zhong)组人(ren)(ren)白(bai)介(jie)素－１１（Ⅰ）研(yan)发(fa)先后被(bei)列入(ru)“九五(wu)”国家(jia)(jia)科技攻(gong)关(guan)计(ji)划、“十(shi)五(wu)”创新(xin)(xin)(xin)药(yao)(yao)物(wu)和中(zhong)(zhong)药(yao)(yao)现代化重(zhong)(zhong)大专项、国家(jia)(jia)“火(huo)炬”计(ji)划项目(mu)、国家(jia)(jia)“创新(xin)(xin)(xin)”计(ji)划项目(mu)、山东省创新(xin)(xin)(xin)药(yao)(yao)物(wu)和中(zhong)(zhong)药(yao)(yao)现代化重(zhong)(zhong)大专项。
重(zhong)组(zu)人白介(jie)素－１１（Ⅰ）临(lin)床用(yong)于肿瘤(liu)(liu)患者放化(hua)疗引起的(de)血(xue)(xue)小(xiao)(xiao)板(ban)(ban)(ban)减少症(zheng)(zheng)，其(qi)作用(yong)是(shi)通(tong)过直接刺激造(zao)血(xue)(xue)干细(xi)胞和(he)(he)巨(ju)(ju)核(he)(he)祖细(xi)胞的(de)增殖(zhi)，诱导巨(ju)(ju)核(he)(he)细(xi)胞的(de)成(cheng)(cheng)熟分(fen)化(hua)，促进体内(nei)血(xue)(xue)小(xiao)(xiao)板(ban)(ban)(ban)的(de)生(sheng)成(cheng)(cheng)，提(ti)高(gao)血(xue)(xue)小(xiao)(xiao)板(ban)(ban)(ban)计数(shu)，有(you)效(xiao)(xiao)预防因(yin)血(xue)(xue)小(xiao)(xiao)板(ban)(ban)(ban)数(shu)目减少引发(fa)的(de)全(quan)(quan)身性(xing)(xing)出血(xue)(xue)症(zheng)(zheng)。东阿阿胶(jiao)历经九年攻(gong)关，在(zai)(zai)攻(gong)克天然(ran)白介(jie)素－１１基因(yin)序列改(gai)造(zao)、细(xi)菌菌株稳定性(xing)(xing)、高(gao)效(xiao)(xiao)纯化(hua)工(gong)艺优化(hua)等(deng)难(nan)题后构建成(cheng)(cheng)功(gong)全(quan)(quan)新的(de)药(yao)物蛋(dan)白结构，近而(er)形成(cheng)(cheng)拥有(you)自主知识产权(quan)的(de)国家一类新药(yao)和(he)(he)防治肿瘤(liu)(liu)化(hua)疗病人血(xue)(xue)小(xiao)(xiao)板(ban)(ban)(ban)减少症(zheng)(zheng)的(de)特(te)效(xiao)(xiao)基因(yin)工(gong)程(cheng)药(yao)。经中国医学科(ke)学院肿瘤(liu)(liu)医院等(deng)１２家医院４年４００多例的(de)临(lin)床试验(yan)证明，该产品治疗和(he)(he)预防化(hua)疗所致血(xue)(xue)小(xiao)(xiao)板(ban)(ban)(ban)降(jiang)低(di)疗效(xiao)(xiao)确切、安(an)全(quan)(quan)，具(ju)有(you)起效(xiao)(xiao)迅(xun)速、使(shi)用(yong)剂(ji)量小(xiao)(xiao)的(de)特(te)点，不(bu)但(dan)能(neng)升高(gao)血(xue)(xue)小(xiao)(xiao)板(ban)(ban)(ban)的(de)数(shu)量，而(er)且缩(suo)短(duan)血(xue)(xue)小(xiao)(xiao)板(ban)(ban)(ban)降(jiang)低(di)的(de)时间(jian)，改(gai)善血(xue)(xue)小(xiao)(xiao)板(ban)(ban)(ban)降(jiang)低(di)的(de)幅度，减少血(xue)(xue)小(xiao)(xiao)板(ban)(ban)(ban)输(shu)注的(de)次(ci)数(shu)，避免因(yin)输(shu)成(cheng)(cheng)分(fen)血(xue)(xue)而(er)造(zao)成(cheng)(cheng)的(de)不(bu)良反应。其(qi)发(fa)育成(cheng)(cheng)熟的(de)巨(ju)(ju)核(he)(he)细(xi)胞，在(zai)(zai)超(chao)微结构上完(wan)全(quan)(quan)正(zheng)(zheng)常，生(sheng)成(cheng)(cheng)的(de)血(xue)(xue)小(xiao)(xiao)板(ban)(ban)(ban)的(de)形态、功(gong)能(neng)和(he)(he)寿命也(ye)均正(zheng)(zheng)常，对血(xue)(xue)小(xiao)(xiao)板(ban)(ban)(ban)的(de)正(zheng)(zheng)常功(gong)能(neng)没有(you)影(ying)响。
东(dong)阿阿胶研(yan)发的(de)(de)重(zhong)组人白(bai)介素－１１（Ⅰ）产品价格明(ming)(ming)显(xian)低于(yu)同类进口药物(wu)，所构(gou)建的(de)(de)全新药物(wu)蛋白(bai)结构(gou)已(yi)被批准为国(guo)家发明(ming)(ming)专利在７月２日山(shan)东(dong)省科技厅组织的(de)(de)科技成果(guo)鉴定会(hui)上，与会(hui)专家认为重(zhong)组人白(bai)介素－１１（Ⅰ）研(yan)发项目达(da)到国(guo)际(ji)先进水平(ping)。
（任儒倬 尹杰 吴延华）
返回顶部
